Acute amebic dysentery requires prompt treatment with a structured two-drug combination. First-line therapy targets both the tissue-invasive and luminal phases of the infection, and the sequence and selection of agents matter.
Clinical disease requires two drugs: a tissue-active nitroimidazole agent paired with a luminal cysticidal agent. The nitroimidazole does not effectively eradicate luminal cysts on its own, so the luminal agent must follow — the two are not given simultaneously. The complete protocol covers agent selection, oral and intravenous options, alternative agents, and exact sequencing criteria.
DOI: 10.1093/ofid/ofy161
Patients with clinical disease require treatment with 2 drugs: an amebicidal tissue-active agent and a luminal cysticidal agent.
The nitroimidazoles do not effectively eradicate luminal cysts and must be followed by a luminal agent.
In patients who are unable to tolerate or absorb oral metronidazole, intravenous metronidazole should be used.